SEC Tracker
Get the app

biote BTMD

biote appoints Marc Beer as Executive Chairman

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract
Exhibit 10.3
Material contract
Exhibit 10.4
Material contract
Exhibit 10.5
Material contract
Exhibit 10.6
Material contract
Exhibit 10.9
Material contract
Exhibit 99.1
Press release
  • Signs a material agreement (1.01)
  • Completes an acquisition or sale of assets (2.01)
  • Takes on a new financial obligation (2.03)
  • Sells unregistered shares (3.02)
  • Changes shareholder rights (3.03)
  • Changes its auditor (4.01)
  • Reports a change in control (5.01)
  • Reports an executive or board change (5.02)
  • Amends its charter or bylaws (5.03)
  • Changes its ethics code (5.05)
  • Changes its shell company status (5.06)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when biote files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. Assembly Biosciences ASMB public float $98M, Jun 30, 2025
  2. Milestone Pharmaceuticals MIST public float $99M, Jun 30, 2025
  3. DiaMedica Therapeutics DMAC public float $96M, Jun 30, 2025
  4. Carisma Therapeutics CARM
  5. Larimar Therapeutics LRMR public float $95M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.